BioLineRx (BLRX) Non Operating Income (2013 - 2025)
BioLineRx (BLRX) posted Non Operating Income of $1.1 million for Q4 2025, down 2.59% on a QoQ basis from $1.2 million in Q3 2025, and down 79.06% year-over-year from $5.4 million in Q4 2024.
BioLineRx (BLRX) has 13 years of Non Operating Income data on file, last reported at $1.1 million in Q4 2025.
- In Q4 2025, Non Operating Income fell 79.06% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $8.1 million (down 56.19% YoY), while the FY2025 annual figure was $8.1 million, down 56.19% from the prior year.
- Non Operating Income retreated to $1.1 million in Q4 2025, from $1.2 million in the prior quarter.
- Across five years, Non Operating Income topped out at $7.8 million in Q2 2024 and bottomed at -$7.7 million in Q2 2023.
- A 5-year average of $976650.0 and a median of $941500.0 in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 311.06% — and 2023, when it slumped 1788.43%.
- Year by year, Non Operating Income stood at $2.2 million in 2021, then soared by 58.85% to $3.6 million in 2022, then fell by 16.43% to $3.0 million in 2023, then soared by 81.15% to $5.4 million in 2024, then sank by 79.06% to $1.1 million in 2025.
- The last three Non Operating Income figures came in at $1.1 million (Q4 2025), $1.2 million (Q3 2025), and -$1.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | -1.85 Mn |
| Mar 31, 2025 | 7.64 Mn |
| Dec 31, 2024 | 5.38 Mn |
| Sep 30, 2024 | 756,000.00 |
| Jun 30, 2024 | 7.81 Mn |
| Mar 31, 2024 | 4.49 Mn |
| Dec 31, 2023 | 2.97 Mn |
| Sep 30, 2023 | -3.14 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -2.92 Mn |
| Dec 31, 2022 | 3.56 Mn |
| Sep 30, 2022 | 389,000.00 |
| Jun 30, 2022 | 458,000.00 |
| Mar 31, 2022 | 1.27 Mn |
| Dec 31, 2021 | 2.24 Mn |
| Sep 30, 2021 | 710,000.00 |
| Jun 30, 2021 | -217,000.00 |
| Mar 31, 2021 | -4.56 Mn |
| Dec 31, 2020 | -5.62 Mn |
| Sep 30, 2020 | 294,000.00 |
| Jun 30, 2020 | -843,000.00 |
| Mar 31, 2020 | 469,000.00 |
| Dec 31, 2019 | 189,000.00 |
| Sep 30, 2019 | 3.06 Mn |
| Jun 30, 2019 | 1.26 Mn |
| Mar 31, 2019 | -340,000.00 |
| Dec 31, 2018 | 1.53 Mn |
| Sep 30, 2018 | -255,000.00 |
| Jun 30, 2018 | 663,000.00 |
| Mar 31, 2018 | 462,000.00 |
| Dec 31, 2017 | 82,000.00 |
| Sep 30, 2017 | -333,000.00 |
| Jun 30, 2017 | -4,000.00 |
| Mar 31, 2017 | -5,000.00 |
| Dec 31, 2016 | 32,000.00 |
| Sep 30, 2016 | -14,000.00 |
| Jun 30, 2016 | 48,000.00 |
| Mar 31, 2016 | 148,000.00 |
| Dec 31, 2015 | 349,000.00 |
| Sep 30, 2015 | 1.98 Mn |
| Jun 30, 2015 | -847,000.00 |
| Mar 31, 2015 | -40,000.00 |
| Dec 31, 2014 | -285,000.00 |
| Sep 30, 2014 | 1.38 Mn |
| Jun 30, 2014 | 279,000.00 |
| Mar 31, 2014 | 1.69 Mn |
| Dec 31, 2013 | -1.44 Mn |
| Sep 30, 2013 | -1.31 Mn |
| Jun 30, 2013 | 436,000.00 |
| Mar 31, 2013 | 3.36 Mn |